4,4,4-Trichlor-3-hydroxybutansaeure-(1)-ethylester | 19486-93-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羟基酸及其衍生物
• 英文名称: 4,4,4-Trichlor-3-hydroxybutansaeure-(1)-ethylester
• 英文别名: Ethyl 3-hydroxy-4,4,4-trichlorobutyrate；ethyl 4,4,4-trichloro-3-hydroxybutanoate
• CAS: 19486-93-2
• 化学式: C₆H₉Cl₃O₃
• mdl: MFCD00087185
• 分子量: 235.495
• InChiKey: RZSBEAZIKBJBBY-UHFFFAOYSA-N

物化性质

• 熔点：
  56-57 °C
• 沸点：
  143-144 °C(Press: 12 Torr)
• 密度：
  1.443±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2918199090

反应信息

• 作为反应物：
  描述：

  4,4,4-Trichlor-3-hydroxybutansaeure-(1)-ethylester 以75%的产率得到
  参考文献：
  名称：

  SEEBACH, D.;RENAUD, PH.;SCHWEIZER, W. B.;ZUEGER, M. F., HELV. CHIM. ACTA, 1984, 67, N 7, 1843-1853

  摘要：

  DOI：
• 作为产物：
  描述：

  4,4,4-Trichloro-3-trimethylsilanyloxy-butyric acid ethyl ester 以 甲醇 为溶剂， 反应 1.0h， 生成 4,4,4-Trichlor-3-hydroxybutansaeure-(1)-ethylester
  参考文献：
  名称：

  Deleris; Dunogues; Babin, European Journal of Medicinal Chemistry, 1981, vol. 16, # 6, p. 533 - 537

  摘要：

  DOI：

文献信息

• AZOLE COMPOUNDS
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1486490A1

  公开（公告）日：2004-12-15

  The present invention provides a compound represented by the formula (I) wherein R1 is a hydrogen atom, a halogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, an optionally substituted hydroxy group, an optionally substituted thiol group or an optionally substituted amino group, A is an optionally substituted cyclic amino group or -NR2-W-D wherein R2 is a hydrogen atom or an alkyl group, W is a bond or a divalent acyclic hydrocarbon group, and D is an optionally substituted cyclic group, an optionally substituted amino group or an optionally substituted acyl group, B is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, X is an oxygen atom, a sulfur atom or an optionally substituted nitrogen atom, and Y is a bond or a divalent acyclic hydrocarbon group, or a salt thereof, which is useful for the prophylaxis or treatment of diabetic neuropathy and the like.

  本发明提供了一种由以下式（I）表示的化合物， 其中R1是氢原子、卤原子、可选择取代的碳氢基团、可选择取代的杂环基团、可选择取代的羟基、可选择取代的硫醇基团或可选择取代的氨基， A是可选择取代的环氨基团或-NR2-W-D，其中R2是氢原子或烷基，W是键或二价的非环烃基团，D是可选择取代的环基团、可选择取代的氨基团或可选择取代的酰基团， B是可选择取代的碳氢基团或可选择取代的杂环基团， X是氧原子、硫原子或可选择取代的氮原子，以及 Y是键或二价的非环烃基团，或其盐，用于预防或治疗糖尿病性神经病变等。
• Latent inhibitors. Part 2. Allylic inhibitors of alcohol dehydrogenase
  作者：Iain MacInnes、David E. Schorstein、Colin J. Suckling、Roger Wrigglesworth

  DOI：10.1039/p19810001103

  日期：——

  3-substituted prop-2-en-1-ols and -1-als, required for studying the latent inhibition of horse liver alcohol dehydrogenase (E.C. 1.1.1.1), are described. Substituents were chosen to cover a range of alkoxide, phenolate, thiolate, and halide leaving groups. Of the compounds studied, only 3-ethylthioprop-2-en-1-ol proved to be a latent inhibitor through oxidation to the corresponding aldehyde, catalysed by

  描述了研究潜在抑制马肝醇脱氢酶（EC 1.1.1.1）所需的多种3-取代的丙-2-烯-1-醇和-1-al的合成。选择取代基以覆盖一定范围的醇盐，酚盐，硫醇盐和卤化物离去基团。在研究的化合物中，只有3-ethylthioprop-2-en-1-ol被酶催化氧化为相应的醛，被证明是潜在的抑制剂。由产物研究和动力学测量表明，由该抑制剂引起的抑制作用的持久性归因于乙硫醇，乙硫醇是由酶催化的醛水解形成的。
• Process for the preparation of (S)- or (R)-4-halo-3-hydroxybutyrates
  申请人：Lonza AG

  公开号：EP1528053A1

  公开（公告）日：2005-05-04

  Process for the preparation of enantiomerically pure (S)- or (R)-4-halo-3-hydroxybutyrates of formula wherein R1 is CH2X, CHX2 or CX3 and X independently represents Cl and/or Br and wherein R2 is C1-6-alkyl, C3-8-cycloalkyl, aryl or aralkyl, each aryl or aralkyl being optionally further substituted with one or more C1-4-alkyl groups and/or halogen atoms, by asymmetric hydrogenation of 4-halo-3-oxobutyric acid esters of formula wherein R1, R2 and X are as defined above in the presence of a catalyst of a ruthenium complex comprising a chiral ligand of the formula

  制备(S)-或(R)-4-卤代-3-羟基丁酸酯的过程，其中公式中的R1为CH2X、CHX2或CX3，X独立表示Cl和/或Br，R2为C1-6-烷基、C3-8-环烷基、芳基或芳基烷基，每个芳基或芳基烷基可以进一步取代一个或多个C1-4-烷基基团和/或卤素原子，通过不对称氢化4-卤代-3-氧代丁酸酯的过程制备，其中公式中的R1、R2和X如上定义，在含有手性配体的钌配合物催化剂的存在下。该手性配体的公式为：
• Azole compounds
  申请人：Sakai Nozomu

  公开号：US20050090534A1

  公开（公告）日：2005-04-28

  The present invention provides a compound represented by the formula (I) wherein R 1 is a hydrogen atom, a halogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, an optionally substituted hydroxy group, an optionally substituted thiol group or an optionally substituted amino group, A is an optionally substituted cyclic amino group or —NR 2 —W-D wherein R 2 is a hydrogen atom or an alkyl group, W is a bond or a divalent acyclic hydrocarbon group, and D is an optionally substituted cyclic group, an optionally substituted amino group or an optionally substituted acyl group, B is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, X is an oxygen atom, a sulfur atom or an optionally substituted nitrogen atom, and Y is a bond or a divalent acyclic hydrocarbon group, or a salt thereof, which is useful for the prophylaxis or treatment of diabetic neuropathy and the like.

  本发明提供了一种化合物，其表示为公式(I)，其中R1是氢原子、卤素原子、可选取代的碳氢基团、可选取代的杂环基团、可选取代的羟基、可选取代的硫醇基或可选取代的氨基；A是可选取代的环状氨基基团或-NR2-W-D，其中R2是氢原子或烷基团，W是键或双价的无环烃基团，D是可选取代的环状基团、可选取代的氨基或可选取代的酰基团；B是可选取代的碳氢基团或可选取代的杂环基团；X是氧原子、硫原子或可选取代的氮原子；Y是键或双价的无环烃基团，或其盐。该化合物对于预防或治疗糖尿病性神经病等方面有用。
• Process for the preparation of (s)-or (r)-4-halo-3-hydroxybutyrates
  申请人：Mettler Hanspeter

  公开号：US20070078279A1

  公开（公告）日：2007-04-05

  Process for the preparation of enantiomerically pure (S)- or (R)-4-halo-3-hydroxybutyrates of formula (I), wherein R 1 is CH 2 X, CHX 2 or CX 3 and X independently represents Cl and/or Br and wherein R 2 is C 1-6 -alkyl, C 3-8 -cycloalkyl, aryl or aralkyl, each aryl or aralkyl being optionally further substituted with one or more C 1-4 -alkyl groups and/or halogen atoms, by asymmetric hydrogenation of 4-halo-3-oxobutyric acid esters of formula (II), wherein R 1 , R 2 and X are as defined above in the presence of a catalyst of a ruthenium complex comprising a chiral ligand of the formula (III).

  制备对映纯(S)-或(R)-4-卤代-3-羟基丁酸酯的过程，其中公式(I)中的R1为CH2X、CHX2或CX3，X独立表示Cl和/或Br，R2为C1-6烷基、C3-8环烷基、芳基或芳基烷基，每个芳基或芳基烷基可以进一步取代一个或多个C1-4烷基基团和/或卤素原子，通过在公式(II)中存在公式(III)的手性配体的钌配合物催化剂的存在下不对称氢化4-卤代-3-酮基丁酸酯来实现。其中R1、R2和X如上所定义。